Cannabis: Pharmacology and toxicology in animals and humans

Addiction

Volumn 91, Issue 11, 1996, Pages 1585-1614

  Adams, Irma B ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; PSYCHOTROPIC AGENT;

DRUG ABUSE; DRUG USE; HUMAN; NONHUMAN; PHARMACOLOGY; REVIEW; SECOND MESSENGER; SIDE EFFECT; TOXICOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CANNABINOIDS; DRUG TOLERANCE; HUMANS; MARIJUANA ABUSE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

EID: 0029830331     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1080/09652149639169     Document Type: Review

References (252)

1. ABEL, E. L. (1970) Marijuana and memory, Nature, 227, 1151-1152.
2. ABEL, E. L. (1979) A Comprehensive Guide to the Cannabis Literature (Westport, CN, Greenwood Press).
3. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in the whole brain, Pharmacology Biochemistry and Behavior, 46, 575-579.
4. ACETO, M. D., SCATES, S. M., LOWE, J. A. & MARTIN, B. R. (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A, European Journal of Pharmacology, 282, R1-R2.
5. ADAMS, R., BAKER, B. & WEARN, R. (1940a) Structure of cannabinol III: synthesis of cannaciona, 1-hydroxy-3-n-amyl-6,6,9-trimenthyl-6-dibenzopyran, Journal of the American Chemical Society, 62, 2204-2207.
6. ADAMS, R., HUNT, M. & CLARK, J. (1940b) Structure of cannabidiol, a product isolated for the marihuana extrace of Minnesota wild hemp, Journal of the American Chemical Society, 62, 196-200.
7. 1-tetrahydrocannabinol and other cannabinoids with emphasis on man, Pharmacological Reviews, 38, 21-43.
8. ALLEBECK, P. (1993) Schizophrenia and cannabis: cause-effect relationship?, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 113-117 (Boca Raton, FL, CRC Press).
9. ASHFAQ, M. K., WATSON, E. S. & ELSOHLY, H. N. (1987) The effect of subacute marijuana smoke inhalation on experimentally induced dermonecrosis by S. aureus infection, Immunopharmacology and Immunotoxicology, 9, 319-331.
10. AUSSEDAT, M. & NIZIOLEK-REINHARDT, S. (1993) Detection of cannabis and other drugs in 120 victims of road accidents, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 73-77 (Boca Raton, FL, CRC Press).
11. 9-tetrahydrocannabinol, cannabinol, and cannabidiol on the immune system in mice: I. In vivo investigation of the primary and secondary immune response, Pharmacology, 26, 1-11.
12. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication, Neuroscience and Biobehavioral Reviews, 16, 55-62.
13. BEARDSLEY, P. M., BALSTER, R. L. & HARRIS, L. S. (1986) Dependence on tetrahydrocannabinol in rhesus monkeys, Journal of Pharmacology and Experimental Therapeutics, 239, 311-319.
14. BENOWITZ, N. L. & JONES, R. T. (1975) Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion, Clinical Pharmacology and Therapeutics, 18, 287-297.
15. BIDAUT-RUSSELL, M., DEVANE, W. A. & HOWLETT, A. C. (1990) Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain, Journal of Neurochemistry, 55, 21-26.
16. 9-tetrahydrocannabinol in the blood pressure of hypertensive rats bearing regenerated adrenal glands, British Journal of Pharmacology, 48, 169-171.
17. BOUABOUUA, M., RINALDI, M., CARAYON, P. et al. (1993) Cannabinoid-receptor expression in human leukocytes, European Journal of Biochemistry, 214, 173-180.
18. BURSTEIN, S., HUNTER, S. A. & RENZULLI, L. (1985) Prostaglandins and cannabis XIV. Tolerance to the stimulatory actions of cannabinoids on arachidonate metabolism, Journal of Pharmacology and Experimental Therapeutics, 235, 87-91.
19. 9-Tetrahydrocannabinol decreases alpha/beta interferon response to Herpes simplex virus type 2 in the B6C3F1 mouse, Proceedings of the Society for Experimental Biology and Medicine, 181, 305-311.
20. CABRAL, G. A., STINNETT, A. L., BAILEY, J. et al. (1991) Chronic marijuana smoke alters alveolar macrophage morphology and protein expression, Pharmacology Biochemistry and Behavior, 40, 643-649.
21. 9-Tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity, Proceedings of the Society for Experimental Biology and Medicine, 199, 255-263.
22. 9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats, Pharmacology, 4, 359-368.
23. CARNEY, J. M., BALSTER, R. L., MARTIN, B. R. & HARRIS, L. S. (1979) Effects of systemic and intraventricular administration of cannabinoids on schedule-controlled responding in the squirrel monkey, Journal of Pharmacology and Experimental Therapeutics, 210, 399-404.
24. CAULFIELD, M. P. & BROWN, D. A. (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism, British Journal of Pharmacology, 106, 231-232.
25. CHAIT, L. D. & PIERRI, J. (1992) Effects of smoked marijuana on human performance: a critical review, in: MURPHY, L. & BARTKE, A. (Eds) Marijuana/Cannabinoids: neurobiology and neurophysiology, pp. 387-423 (Boca Raton, FL, CRC Press).
26. 2+ mobilization of exocrine pancreas, Molecular Pharmacology, 34, 543-548.
27. CHESHER, G. (1995) Cannabis and road safety: an outline of the research studies to examine the effects of cannabis on driving skills and actual driving performance, in: The Effects of Drugs (Other Than Alcohol) on Road Safety, pp. 67-96 (Melbourne, Australia, Road Safety Committee, Parliament of Victoria).
28. CLARK, S., GREENE, C., KARR, G., MACCANNELL, K. & MILSTEIN, S. (1974) Cardiovascular effects of marihuana in man, Canadian Journal of Physiology, 52, 706-719.
29. CLARKE, R. C. (1981) Marijuana Botany (Berkeley, California, Ronin Publishing).
30. COCCHETTO, D. M., OWENS, S. M., PEREZ-REYES, M., DI GUISEPPI, S. & MILLER, L. L. (1981) Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man, Psychopharmacology, 75, 158-164.
31. COHEN, M. J. & RICKLES JR, W. H. (1974) Performance on a verbal learning task by subjects of heavy past marihuana usage, Psychopharmacologia (Berlin), 37, 323-330.
32. COLASANTI, B., LINDAMOOD, C. & CRAIG, C. (1982) Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats, Pharmacology Biochemistry and Behavior, 16, 573-578.
33. COMPTON, D. R., DEWEY, W. L. & MARTIN, B. R. (1990) Cannabis dependence and tolerance production, in: ERICKSON, C. K., JAVORS, M. A. & MORGAN, W. W. (Eds) Addiction Potential of Abused Drugs and Drug Classes, pp. 129-147 (Binghampton, NY, The Hayworth Press, Inc.).
34. 9-tetrahydrocannabinol, Journal of Pharmacology and Experimental Therapeutics, 263, 1118-1126.
35. COMPTON, D. R., JOHNSON, M. R., MELVIN, L. S. & MARTIN, B. R. (1992b) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents, Journal of Pharmacology and Experimental Therapeutics, 260, 201-209.
36. COMPTON, D. R., RICE, K. C., DE COSTA, B. R. et al. (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities, Journal of Pharmacology and Experimental Therapeutics, 265, 218-226.
37. CONE, E. J. (1990) Marijuana effects and urinalysis after passive inhalation and oral ingestion, NIDA Research Monograph Series, 99, 88-96.
38. CONE, E. J. & HUESTIS, M. A. (1993) Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marihuana usage, Therapeutic Drug Monitoring, 15, 527-532.
39. CONSROE, P., MARTIN, A. R. & FISH, B. S. (1982) Use of potential rabbit model for structure-behavioral activity studies of cannabinoids, Journal of Medicinal Chemistry, 25, 596-599.
40. CRAWLEY, J. N., CORWIN, R. L., ROBINSON, J. K., FELDER, C. C., DEVANE, W. A. & AXELROD, J. (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents, Pharmacology Biochemistry and Behavior, 46, 967-972.
41. DAUL, C. B. & HEALTH, R. G. (1975) The effect of chronic marihuana usage on the immunological status of rhesus monkeys, Life Sciences, 17, 875-882.
42. 9-tetrahydrocannabinol on body temperature in mice, Psychopharmacology, 69, 299-305.
43. DAVIES, P., SORNBERGER, G. C. & HUBER, G. L. (1979) Effects of experimental marijuana and tobacco smoke inhalation on alveolar macrophages, Laboratory Investigation, 41, 220-223.
44. DAX, E. M., PILOTTE, N. S., ALDER, W. H., NAGEL, J. E. & LANGE, W. R. (1989) The effects of 9-enetetrahydrocannabinol on hormone release and immune function, Journal of Steroid Biochemistry, 34, 263-270.
45. DEADWYLER, S. A., HAMPSON, R. E., BENNETT, B. A. et al. (1993) Cannabinoids modulate potassium current in cultured hippocampal neurons, Receptors and Channels, 1, 121-134.
46. DEUTSCH, D. G. & CHIN, S. A. (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist, Biochemical Pharmacology, 46, 791-796.
47. DEVANE, W. A. & AXELROD, J. (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes, Proceedings of National Academy of Science USA, 91, 6698-6701.
48. DEVANE, W. A., DYSARZ, F. A., JOHNSON, M. R., MELVIN, L. S. & HOWLETT, A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain, Molecular Pharmacology, 34, 605-613.
49. DEVANE, W. A., HANUS, L., BREUER, A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946-1949.
50. DEWEY, W. L. (1986) Cannabinoid pharmacology, Pharmacological Reviews, 38, 151-178.
51. DEWEY, W. L., MARTIN, B. R. & MAY, E. L. (1984) Cannabinoid stereoisomers: pharmacological effects, in: SMITH, D. F. (Ed.) CRC Handbook of Stereoisomers: drugs in psychopharmacology, 317-326 (Boca Raton, FL, CRC Press).
52. 9-tetrahydrocannabinol, Biochemical Pharmacology, 22, 399-405.
53. 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats, European Journal of Pharmacology, 12, 382-384.
54. DIAZ, S., SPECTOR, S. & COFFEY, R. G. (1993) Suppression of lymphocyte adenosine-3′,5′-cyclic monophosphate (cAMP) by delta-9-tetrahydrocannabinol, International Journal of Immunopharmacology, 15, 523-532.
55. DILL, J. A. & HOWLETT, A. C. (1988) Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs, Journal of Pharmacology and Experimental Therapeutics, 244, 1157-1163.
56. DI MARZO, V., FONTANA, A., CADAS, H. et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature, 372, 686-691.
57. DRUMMER, O. (1994) Drugs and drivers killed in Australian road traffic accidents: the use of responsibility analysis to investigate the contribution of drugs to fatal accidents (Victorian Institute of Forensic Pathology, Monash University).
58. EDERY, H., GRUNFELD, Y., BEN-ZVI, Z. & MECHOULAM, R. (1971) Structural requirements for cannabinoid activity, Annals of the New York Academy of Sciences, 191, 40-53.
59. EDERY, H., GRUNFELD, Y., PORATH, G., BEN-ZVI, Z., SHANI, A. & MECHOULAM, R. (1972) Structure-activity relationships in the tetrahydrocannabinol series: modifications on the aromatic ring in the side-chain, Arzneimittel-Forschung, 22, 1995-2003.
60. ELSOHLY, M. A. & ROSS, S. A. (1994) Quarterly Report, NIDA Potency Monitoring Project, Report No. 50 (Rockville, MD, National Institute on Drug Abuse).
61. FAN, F., TAO, Q., ABOOD, M. & MARTIN, B. R. (1996) Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebullum of CP 55,940-tolerant mice, Brain Research, 706, 13-20.
62. FELDER, C. C., BRILEY, E. M., AXELROD, J., SIMPSON, J. T., MACKIE, K. & DEVANE, W. A. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction, Proceedings of the National Academy of Science USA, 90, 7656-7660.
63. FELDER, C. C., VELUZ, J. S., WILLIAMS, H. L., BRILEY, E. M. & MATSUDA, L. A. (1992) Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones, Molecular Pharmacology, 42, 838-845.
64. 9-tetrahydrocannabinol in chimpanzees, Science, 179, 490-492.
65. FINK, M., VOLAVKA, J., PANAYIOTOPOULOS, C. P. & STEFANIS, C. (1976) Quantitative EEG studies of marihuana, delta-9-tetrahydrocannabinol and hashish in man, in: BRAUDE, M. C. & SZARA, S. (Eds) The Pharmacology of Marihuana, pp. 383-391 (New York, Raven Press).
66. 9-Tetrahydrocannabinol inhibition of tumor necrosis factor-α: suppression of post-translational events, Journal of Pharmacology and Experimental Therapeutics, 267, 1558-1565.
67. 9-tetrahydrocannabinol, British Journal of Pharmacology, 75, 409-414.
68. FOLTIN, R. W., FISCHMAN, M. W., BRADY, J. V. et al. (1990) Motivational effects of smoked marijuana: behavioral contingencies and low-probability activities, Journal of the Experimental Analysis of Behavior, 53, 5-19.
69. FOLTIN, R. W., FISCHMAN, M. W., BRADY, J. V., KELLY, T. H., BERNSTEIN, D. J. & NELLIS, M. J. (1989) Motivational effects of smoked marihuana: behavioral contingencies and high-probability recreational activities, Pharmacology Biochemistry and Behavior, 34, 871-877.
70. FRASER, J. D. (1949) Withdrawal symptoms in cannabis-indica addicts, Lancet, 257, 747-748.
71. FRIDE, E. & MECHOULAM, R. (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent, European Journal of Pharmacology, 231, 313-314.
72. GAONI, Y. & MECHOULAM, R. (1964) Isolation, structure, and partial synthesis of an active constituent of hashish, Journal of the American Chemical Society, 86, 1646-1647.
73. GEORGE, H. R. (1970) Two psychotic episodes associated with cannabis, British Journal of Addiction, 65, 119-121.
74. GéRARD, C. M., MOLLEREAU, C., VASSART, G. & PARMENTIER, M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis, Biochemistry Journal, 279, 129-134.
75. 9-THC and CP-55,940 in rats and rhesus monkeys, Journal of Pharmacology and Experimental Therapeutics, 262, 479-486.
76. 9-Tetrahydrocannabinol and the extrapyramidal system, Psychopharmacology, 54, 87-99.
77. 9-THC in the rat, Neuropharmacology, 17, 137-144.
78. GRINSPOON, L. & BAKALAR, J. B. (1993) Marihuana: the forbidden medicine (New Haven, CT, Yale University Press).
79. GRUNFELD, Y. & EDERY, H. (1969) Psychopharmacological activity of the active constituents of hashish and some related cannabinoids, Psychopharmacologia (Berlin), 14, 200-210.
80. GUPTA, S., GRIECO, M. H. & CUSHMAN, P. (1974) Impairment of rosette-forming T lymphocytes in chronic marihuana smokers, New England Journal of Medicine, 291, 874-877.
81. HACHEM, D. G. (1994) Illicit drug use in Beirut and Lebanon, Epidemiologic Trends in Drug Abuse: Community Epidemiology Work Group, vol. II, pp. 335-344 (Washington, DC, US Department of Health and Human Services).
82. HALL, W., JOHNSTON, L. & DONNELLY, N. (1996) Epidemiological evidence on patterns of cannabis use and their health consequences, World Health Organization Project on Health Implications of Cannabis Use, in press.
83. HALL, W., SOLOWIJ, N. & LEMON, J. (1994) The health and psychological consequences of cannabis use, The National Task Force On Cannabis, Sydney, Australia.
84. HANUS, L., GOPHER, A., ALMOG, S. & MECHOULAM, R. (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor, Journal of Medicinal Chemistry, 36, 3032-3034.
85. HARRIS, L. S., CARCHMAN, R. A. & MARTIN, B. R. (1978) Evidence for the existence of specific cannabinoid binding sites, Life Sciences, 22, 1131-1138.
86. HARRIS, R. A. & STOKES, J. A. (1982) Cannabinoids inhibit calcium uptake by brain synaptosomes, Journal of Neuroscience, 2, 443-447.
87. 9-tetrahydrocannabinol in rhesus monkeys, Psychopharmacologia, 37, 23-29.
88. HAYCOCK, D. A., KUSTER, J. E., STEVENSON, J. I., WARD, S. J. & D'AMBRA, T. (1991) Characterization of aminoalkylindole binding: selective displacement by cannabinoids, in: HARRIS, L. S. (Ed.) Problems of Drug Dependence 1990: Proceedings of the 52nd Annual Scientific Meeting, pp. 304-305 (Washington, DC, US Govt Printing Office).
89. HEATH, R. G., FITZJARRELL, A. T., FONTANA, C. J. & GAREY, R. E. (1980) Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys, Biological Psychiatry, 15, 657-690.
90. HEISHMAN, S. J., HUESTIS, M. A., HENNINGFIELD, J. E. & CONE, E. J. (1990) Acute and residual effects of marijuana: profiles of plasma, THC levels, physiological subjective, and performance measures, Pharmacology Biochemistry and Behavior, 37, 561-565.
91. HENRY, D. J. & CHAVKIN, C. (1995) Activation of inwardly rectifying potassium channels (GIRKl) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes, Neuroscience Letters, 186, 91-94.
92. HERKENHAM, M., GROEN, B. G. S., LYNN, A. B., DE COSTA, B. R. & RICHFIELD, E. K. (1991a) Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum, Brain Research, 552, 301-310.
93. HERKENHAM, M., LYNN, A. B., DE COSTA, B. R. & RICHFIELD, E. K. (1991b) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat, Brain Research, 547, 267-274.
94. HERKENHAM, M., LYNN, A. B., JOHNSON, M. R., MELVIN, L. S., DE COSTA, B. R. & RICE, K. C. (1991c) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study, Journal of Neuroscience, 11, 563-583.
95. HERKENHAM, M., LYNN, A. B., LITTLE, M. D. et al. (1990) Cannabinoid receptor localization in the brain, Proceedings of the National Academy of Sciences USA, 87, 1932-1936.
96. 9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells, Journal of Pharmacology and Experimental Therapeutics, 264, 294-307.
97. HILL, S. H., SCHWIN, R., POWELL, B. & GOODWIN, D. W. (1973) State-dependent effects of marihuana on human memory, Nature, 243, 241-242.
98. 9-tetrahydrocannabinol: tolerance to the stimulus effects, Psychopharmacology, 36, 243-253.
99. 6-tetrahydrocannabinol from marijuana, Journal of the American Chemical Society, 88, 1832-1833.
100. HOLLISTER, L. E. (1986) Health aspects of cannabis, Pharmacological Reviews, 38, 1-20.
101. HOLLISTER, L. E. (1988) Marijuana and immunity, Journal of Psychoactive Drugs, 20, 3-8.
102. HOSKO, M. J., SCHMELING, W. T. & HARDMAN, H. F. (1981) Evidence for a caudal brainstem site of action for cannabinoid induced hypothermia, Research Bulletin, 6, 251-258.
103. HOWLETT, A. C., EVANS, D. M. & HOUSTON, D. B. (1992) The cannabinoid receptor, in: MURPHY, L. & BARTKE, A. (Eds) Marijuana/Cannabinoids: neurobiology and neurophysiology, pp. 35-72 (Boca Raton, FL, CRC Press).
104. HOWLETT, A. C. & FLEMING, R. M. (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes, Molecular Pharmacology, 26, 532-538.
105. HOWLETT, A. C., JOHNSON, M. R., MELVIN, L. S. & MILNE, G. M. (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model, Molecular Pharmacology, 33, 297-302.
106. i in the inhibition of adenylate cyclase by cannabimimetic drugs, Molecular Pharmacology, 29, 307-313.
107. HUESTIS, M. A., HENNINGFIELD, J. E. & CONE, E. J. (1992) Blood cannabinoids: I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana, Journal of Analytical Toxicology, 16, 276-282.
108. HUESTIS, M. A., SAMPSON, A. H., HOLICKY, B. J., HENNINGFIELD, J. E. & CONE, E. J. (1992) Characterization of the absorption phase of marijuana smoking, Clinical Pharmacology and Therapeutics, 52, 31-41.
109. JANSEN, E. M., HAYCOCK, D. A., WARD, S. J. & SEYBOLD, V. S. (1992) Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles, Brain Research, 575, 93-102.
110. JÄRBE, T. U. & HILTUNEN, A. J. (1987) Cannabimimetic activity of cannabinol in rats and pigeons, Neuropharmacology, 26, 219-228.
111. JÄRBE, T. U. C. (1978) Delta-9-tetrahydrocannabinol: tolerance after noncontingent exposure in rats, Archives Internationales de Pharmacodynamie et de Therapie, 231, 49-59.
112. JÄRBE, T. U. C., HILTUNEN, A. J., MATHIS, D. A., HANUS, L., BREUER, A. & MECHOULAM, R. (1993) Discriminative Stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison, Journal of Pharmacology and Experimental Therapeutics, 264, 561-569.
113. JÄRBE, T. U. C. & MATHIS, D. A. (1992) Dissociative and discriminative stimulus functions of cannabinoids/cannabimimetics, in: MURPHY, L. & BARTKE, A. (Eds) Marijuana/Cannabinoids: neurobiology and neurophysiology, pp. 425-458 (Boca Raton, FL, CRC Press).
114. JENKINS, A. J., MILLS, L. C., DARWIN, W. D., HUESTIS, M. A., CONE, E. J. & MITCHELL, J. M. (1993) Validity testing of the EZ-SCREEN® cannabinoid test, Journal of Analytical Toxicology, 17, 292-298.
115. JOHANSSON, E., AGURELL, S., HOLLISTER, L. E. & HALLDIN, M. M. (1988) Prolonged apparent half-life of delta-9-tetrahydrocannabinol in plasma of chronic marijuana users, Journal of Pharmacy and Pharmacology, 40, 374-375.
116. JOHNSON, S. & DOMINO, E. (1971) Some cardiovascular effects of marihuana smoking in normal volunteers, Clinical Pharmacology Therapy, 12, 762-768.
117. JOHNSTON, L. D., O'MALLEY, P. M. & BACHMAN, J. G. (1995) National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1994, vol. I (Washington, DC, US Department of Health and Human Services).
118. 1-tetrahydrocannabinol, Biochemical Pharmacology, 23, 439-446.
119. JONES, R. T. (1983) Cannabis tolerance and dependence, in: FEHR, K. O. & KALANT, H. (Eds) Cannabis and Health Hazards, pp. 617-689 (Toronto, Addiction Research Foundation).
120. JONES, R. T. & BENOWITZ, N. (1976) The 30-day trip - Clinical studies of cannabis tolerance and dependence, in: BRAUDE, M. C. & SZARA, S. (Eds) Pharmacology of Marihuana, pp. 627-642 (New York, Raven Press).
121. JONES, R. T., BENOWITZ, N. & BACHMAN, J. (1976) Clinical studies of cannabis tolerance and dependence, Annals of the New York Academy of Science, 282, 221-239.
122. JONES, R. T., BENOWITZ, N. L. & HERNING, R. I. (1981) Clinical relevance of cannabis tolerance and dependence, Journal of Clinical Pharmacology, 21, 143S-152S.
123. KAMINSKI, N. E., ABOOD, M. E., KESSLER, F. K., MARTIN, B. R. & SCHATZ, A. R. (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation, Molecular Pharmacology, 42, 736-742.
124. 9-tetrahydrocannabinol and kindling by electrical and chemical stimuli in mice, Neuropharmacology, 23, 1315-1320.
125. KARLER, R., CALDER, L. D. & TURKANIS, S. A. (1984) Changes in CNS sensitivity to cannabinoids with repeated treatment: tolerance and auxoesthesia, in: SHARP, C. W. (Ed.) Mechanisms of Tolerance and Dependence, pp. 312-322 (Washington, DC, US Govt Printing Office).
126. 9-tetrahydrocannabinol-tolerant rats, Psychopharmacology, 55, 243-249.
127. KAYMAKCALAN, S. (1973) Tolerance to and dependence on cannabis, Bulletin on Narcotics, 25, 39-47.
128. KLEIN, T. W. & FRIEDMAN, H. (1990) Modulation of murine immune cell function by marijuana components, in: WATSON, R. R. (Ed.) Drugs of Abuse and Immune Function, pp. 87-111 (Boca Raton, FL, CRC Press).
129. KLEIN, T. W., NEWTON, C. & FRIEDMAN, H. (1994) Resistance to Legionella pneumophilia suppressed by the marijuana component, tetrahydrocannabinol, Journal of Infectious Disease, 169, 1177-1179.
130. KLEIN, T. W., NEWTON, C., WIDEN, R. & FRIEDMAN, H. (1985) The effect of delta-9-tetrahydrocannabinol and 11 -hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses, Journal of Immunopharmacology, 7, 451-466.
131. 9-Tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila, Journal of Pharmacology and Experimental Therapeutics, 267, 635-640.
132. KOKKEVI, A. (1994) The 1993 general population survey in Greece: gender differences in illicit drug use and their implications for planning ethnographic studies, Epidemiologic Trends in Drug Abuse: Community Epidemiology Work Group, vol. II, pp. 329-333 (Washington, DC, US Department of Health and Human Services).
133. 9-tetrahydrocannabinol: behavioral effects and tolerance development, Journal of Pharmacology and Experimental Therapeutics, 159, 61-65.
134. KRUSZKA, K. K. & GROSS, R. W. (1994) The ATP- and CoA-independent synthesis of arachidonoylethanolamide, Journal of Biological Chemistry, 269, 14345-14348.
135. LAU, R., TUBERGEN, D., BARR, M., DOMINO, E., BENOWTTZ, N. & JONES, R. (1976) Phytohemagglutinin-induced lymphocyte transformation in humans receiving delta-9-tetrahydrocannabinol, Science, 192, 905-807.
136. 1-tetrahydrocannabinol and other cannabinoids in spin-labeled liposomes and their relationship to mechanisms of general anesthesia, Molecular Pharmacology, 11, 595-602.
137. LEMBERGER, L. (1984) Clinical evaluation of cannabinoids in the treatment of disease, in: HARVEY, D. J. (Ed.) Marihuana '84: Proceedings of the Oxford Symposium on Cannabis, p. 673 (Oxford, UK, IRL Press Ltd).
138. LEMBERGER, L. & RUBIN, A. (1978) Cannabis: the role of metabolism in the development of tolerance, Drug Metabolism Reviews, 8, 59-68.
139. LEMBERGER, L., WEISS, J. L., WATANABE, A. M., GALANTER, I. M., WYATT, R. J. & CARDON, P. V. (1972) Delta-9-tetrahydrocannabinol: temporal correlation of the psychologic effects and blood levels after various routes of administration, New England Journal of Medicine, 286, 685-688.
140. LICHTMAN, A. H., DIMEN, K. R. & MARTIN, B. R. (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats, Psychopharmacology, 119, 282-290.
141. LITTLE, P. J., COMPTON, D. R., JOHNSON, M. R., MELVIN, L. S. & MARTIN, B. R. (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice, Journal of Pharmacology and Experimental Therapeutics, 247, 1046-1051.
142. 8-tetrahydrocannabinol, Pharmacology Biochemistry and Behavior, 32, 661-666.
143. LOEWE, S. (1947) Bioassay by direct potency estimation, Science, 107, 89-91.
144. LOPEZ-CEPERO, M., FRIEDMAN, M., KLEIN, T. & FRIEDMAN, H. (1986) Tetrahydrocannabinol induced suppression of macrophages spreading and phagocytic activity in vitro, Journal of Leukocyte Biology, 39, 679-686.
145. LUO, Y. D., PATEL, M. K., WIEDERHOLD, M. D. & OU, D. W. (1992) Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins, International Journal of Immunopharmacology, 14, 49-56.
146. LYNN, A. & HERKENHAM, M. (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids, Journal of Pharmacology and Experimental Therapeutics, 268, 1612-1623.
147. MACKIE, K., DEVANE, W. & HILLE, B. (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, Molecular Pharmacology, 44, 498-503.
148. MACKIE, K. & HILLE, B. (1992) Cannabinoids inhibit N-type calcium channels in neurobalstoma-glioma cells, Proceedings of the National Academy of Science USA, 89, 3825-3829.
149. 9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys, Behavioural Pharmacology, 5, 219-225.
150. 9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain, European Journal of Pharmacology, 202, 373-378.
151. 9-tetrahydrocannabinol in mice, in: HARVEY, D. J. (Ed.) Marihuana '84, Proceedings of the Oxford Symposium on Cannabis, pp. 685-692 (Oxford, IRL Press).
152. MARTIN, B. R. (1986) Cellular effects of cannabinoids, Pharmacological Reviews, 38, 45-74.
153. MARTIN, B. R., BALSTER, R. L., RAZDAN, R. K., HARRIS, L. S. & DEWEY, W. L. (1981) Behavioral comparisons of the stereoisomers of tetrahydrocannabinols, Life Sciences, 29, 565-574.
154. MARTIN, B. R., COMPTON, D. R., THOMAS, B. F. et al. (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs, Pharmacology Biochemistry and Behavior, 40, 471-478.
155. 9-Tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs, Journal of Pharmacology and Experimental Therapeutics, 196, 128-144.
156. MATHEW, R. J. & WILSON, W. H. (1992) The effects of marijuana on cerebral blood flow and metabolism, in: MURPHY, L. & BARTKE, A. (Eds) Marijuana/Cannabinoids: neurobiology and neurophysiology, pp. 337-386 (Boca Raton, FL, CRC Press).
157. MATHEW, R. J. & WILSON, W. H. (1993) Acute changes in cerebral blood flow after smoking marijuana, Life Sciences, 52, 757-767.
158. MATHEW, R. J., WILSON, W. H., HUMPHREYS, D. F., LOWE, J. V. & WIETHE, K. E. (1992) Regional cerebral blood flow after marijuana smoking, Journal of Cerebral Blood Flow and Metabolism, 12, 750-758.
159. MATSUDA, L. A., LOLAIT, S. J., BROWNSTETN, M. J., YOUNG, A. C. & BONNER, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561-564.
160. MCMILLAN, D. E., DEWEY, W. L. & HARRIS, L. S. (1971) Characteristics of tetrahydrocannabinol tolerance, Annals of the New York Academy of Science, 191, 83-99.
161. 9-Trans-tetrahydrocannabinol in pigeons: tolerance to the behavioral effects, Science, 169, 501-503.
162. MECHOULAM, R. (1986) Appendices, in: MECHOULAM, R. (Ed.) Cannabinoids as Therapeutic Agents, pp. 167-176 (Boca Raton, FL, CRC Press).
163. MECHOULAM, R., BREUER, A., JARBE, T. U. C., HILTUNEN, A. J. & GLASER, R. (1990) Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids, Journal of Medicinal Chemistry, 33, 1037-1043.
164. MECHOULAM, R. & FEIGENBAUM, J. J. (1987) Towards cannabinoid drugs, Progress in Medicinal Chemistry, 24, 159-207.
165. MECHOULAM, R., FEIGENBAUM, J. J., LANDER, N. et al. (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity, Experientia, 44, 762-764.
166. MECHOULAM, R., HANUS, L. & MARTIN, B. R. (1994) The search for endogenous ligands of the cannabinoid receptor, Biochemical Pharmacology, 48, 1537-1544.
167. MELGES, F. T., TINKLENBERG, J. R., HOLLISTER, L. E. & GILLESPIE, H. K. (1970) Marihuana and temporal disintegration, Science, 168, 1118-1120.
168. MELVIN, L. S. & JOHNSON, M. R. (1987) Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids, in: RAPAKA, R. S. & MAKRIYANNIS, A. (Eds) Structure-Activity Relationships of the Cannabinoids, pp. 31-47 (Washington, DC, US Govt Printing Office).
169. MELVIN, L. S., JOHNSON, M. R., HARBERT, C. A., MILNE, G. M. & WEISSMAN, A. (1984) A cannabinoid derived prototypical analgesic, Journal of Medicinal Chemistry, 27, 67-71.
170. MERRITT, J., CRAWFORD, W., ALEXANDER, P., ANDUZE, A. & GELBART, S. (1980) Effects of marihuana on intraocular and blood pressure in glaucoma, Ophthamology, 87, 222-228.
171. 9-tetrahyrocannabinol in rats, Psychopharmacology, 67, 195-202.
172. MORAHAN, P. S., KLYKKEN, P. C., SMITH, S. H., HARRIS, L. S. & MUNSON, A. E. (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and Herpes simplex virus, Infection and Immunity, 23, 670-674.
173. MOUNTJOY, K. G., ROBBINS, L. S., MORTRUD, M. T. & CONE, R. D. (1992) The cloning of a family of genes that encode the melanocortin receptors, Science, 257, 1248-1251.
174. MUNRO, S., THOMAS, K. L. & ABU-SHAAR, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61-64.
175. MUNSON, A. E. & FEHR, K. O. (1983) Immunological effects of cannabis, in: FEHR, K. O. & KALANT, H. (Eds) Cannabis and Health Hazards: proceedings of an ARF/WHO Scientific Meeting on adverse health and behavioral consequences of cannabis use, pp. 257-354 (Toronto, Addiction Research Foundation).
176. MUSTO, D. F. (1987) The American Disease: origins of narcotic control (New York, Oxford University Press).
177. NAHAS, G. (1993) General toxicity of cannabis, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 5-17 (Boca Raton, FL, CRC Press).
178. NAHAS, G., SUCIU-FOCA, N., ARMAND, J. P. & MORISHIMA, A. (1974) Inhibition of cellular mediated immunity in marihuana smokers, Science, 183, 419-420.
179. NAHAS, G. G., MORISHIMA, A. & DESOIZE, B. (1977) Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes, Federation Proceedings, 36, 1748-1752.
180. NAHAS, G. G. & OSSWEMAN, E. F. (1991) Altered serum immunoglobulin concentration in chronic marijuana smokers, in: FRIEDMAN, H., SPECTOR, S. & KLEIN, T. W. (Eds) Drugs of Abuse, Immunity, and Immunodeficiency, pp. 25-32 (New York, Plenum Press).
181. 9-tetrahydrocannabinol (THC) on memory in the rat, Drug Alcohol Dependence, 28, 167-175.
182. NEGRETE, J. C. (1993) Effects of cannabis on schizophrenia, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 105-112 (Boca Raton, FL, CRC Press).
183. OHLSSON, A., LINDGREN, J.-E., WAHLEN, A., AGURELL, S., HOLLISTER, L. E. & GILLESPIE, H. K. (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking, Clinical Pharmacology and Therapeutics, 28, 409-416.
184. 1-tetrahydrocannabinol in heavy and light cannabis users, Biomedical Mass Spectrometry, 9, pp. 6-10.
185. OVIEDO, A., GLOWA, J. & HERKENHAM, M. (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study, Brain Research, 616, 293-302.
186. PACHECO, M. A., WARD, S. J. & CHILDERS, S. R. (1993) Identification of cannabinoid receptors in cultures of rat cerebellar granule cells, Brain Research, 603, 102-110.
187. PATON, W. D. & PERTWEE, R. G. (1972) Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism, British Journal of Pharmacology, 44, 250-261.
188. PEREZ-REYES, M., HICKS, R. E., BUMBERRY, J., JEFFCOAT, A. R. & COOK, C. E. (1988) Interaction between marihuana and ethanol: effects on psychomotor performance, Alcohol Clinical & Experimental Research, 12, 268-276.
189. PEREZ-REYES, M., OWENS, S. M. & DI GUISEPPI, S. (1981) The clinical pharmacology and dynamics of marijuana cigarette smoking, Journal of Clinical Pharmacology, 21, 201S-207S.
190. 1-tetrahydrocannabinol, British Journal of Pharmacology, 51, 391-397.
191. PERTWEE, R. (1992) In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators, in: MURPHY, L. & BARTKE, A. (Eds) Marihuana/Cannabinoids: neurobiology and neurophysiology, pp. 165-218 (Boca Raton, FL, CRC Press).
192. PERTWEE, R. G. (1988) The central neuropharmacology of psychotropic cannabinoids, Pharmacology and Therapeutics, 36, 189-261.
193. PERTWEE, R. G., STEVENSON, L. A. & GRIFFIN, G. (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide, British Journal of Pharmacology, 110, 1483-1490.
194. PERTWEE, R. G. & WICKENS, A. P. (1991) Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids, Neuropharmacology, 30, 237-244.
195. PLASSE, T. F., GORTER, R. W., KRASNOW, S. H., LANE, M., SHEPARD, K. V. & WADLEIGH, R. G. (1991) Recent clinical experience with Dronabinol, Pharmacology Biochemistry and Behavior, 40, 695-700.
196. POKLIS, A., MAGINN, D. & BARR, J. L. (1987) Drug findings in 'Driving Under the Influence of Drugs' cases: a problem of illicit drug use, Drug and Alcohol Dependence, 20, 57-62.
197. POPE, H. G., GRUBER, A. J. & YURGELUN-TODD, D. (1995) The residual neuropsychological effects of cannabis: the current status of research, Drug and Alcohol Dependence, 38, 25-34.
198. PROSS, S. H., NAKANO, Y., WIDEN, R. et al. (1992) Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators, International Journal of Immunopharmacology, 14, 1019-1027.
199. RACHELEFSKY, G. S., OPELZ, G., MICKEY, M. R. et al. (1976) Intact humoral and cell-mediated immunity in chronic marijuana smoking, Journal of Allergy and Clinical Immunology, 58, 483-490.
200. RAZDAN, R. K. (1986) Structure-activity relationships in cannabinoids, Pharmacological Reviews, 38, 75-149.
201. RAZDAN, R. K. (1987) Structure-activity relationships in cannabinoids: an overview, in: RAPAKA, R. S. & MAKRIYANNIS, A. (Eds) Structure-Activity Relationships of the Cannabinoids, pp. 3-14 (Washington, DC, US Govt Printing Office).
202. RINALDI-CARMONA, M., BARTH, F., HÉAULME, M. et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, Federation of European Biochemical Societies Letters, 350, 240-244.
203. ROBBE, H. W. J. (1994) Influence of Marijuana on Driving (Maastricht, Institute for Human Psychopharmacology, University of Limberg).
204. 9-tetrahydrocannabinol treatment, Pharmacology Biochemistry and Behavior, 47, 33-40.
205. ROMERO, J., GARCíA, L., FERNÁNDEZ-RUIZ, J. J., CEBEIRA, M. & RAMOS, J. A. (1995) Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Δ-tetrahydrocannabinol, Pharmacology Biochemistry and Behavior, 51, 731-737.
206. ROSENKRANTZ, H. (1983) Cannabis, marihuana, and cannabinoid toxicological manifestations in man and animals, in: FEHR, K. O. & KALANT, H. (Eds) Cannabis and Health Hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use, pp. 91-176 (Toronto, Addiction Research Foundation).
207. SCHAEFER, C., BRACKETT, D., GUNN, C. & DUBOWSKI, K. (1979) Decreased platelet aggregation following marihuana smoking in man, Journal of Oklahoma State Medical Association, 72, 435-436.
208. SCHWARTZ, R. H. (1993) Chronic marihuana smoking and short-term memory impairment, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 61-71 (Boca Raton, FL, CRC Press).
209. SCHWARTZFARB, L., NEEDLE, M. & CHAVEZ-CHASE, M. (1974) Dose-related inhibition of leukocyte migration by marijuana and delta-9-tetrahydrocannabinol (THC) in vitro, Journal of Clinical Pharmacology, 14, 35-41.
210. SHERMAN, M. P., ROTH, M. D., GONG, H. & TASHKIN, D. P. (1991) Marijuana smoking, pulmonary function, and lung macrophage oxidant release, Pharmacology Biochemistry and Behavior, 40, 663-669.
211. 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines, Life Sciences, 54, 1281-1289.
212. 1-tetrahydrocannabinol by rats tolerant to cannabis, Canadian Journal of Physiology and Pharmacology, 52, 1154-1166.
213. SILVERMAN, A. Y., DARNELL, B. J., MONTIEL, M. M., SMITH, C. G. & ASCH, R. H. (1982) Response of rhesus monkey lymphocytes to short-term administration of THC, Life Sciences, 30, 107-115.
214. SILVERSTEIN, M. J. & LESSIN, P. J. (1974) Normal skin test response in chronic marijuana users, Science, 186, 740-741.
215. SLIKKER JR, W., PAULE, M. G., ALI, S. F., SCALLET, A. C. & BAILEY, J. R. (1992) Behavioral, neurochemical, and neurohistological effects of chronic marijuana smoke exposure in the nonhuman primate, in: MURPHY, L. & BARTKE, A. (Eds) Marijuana/Cannabinoids: neurobiology and neurophysiology, pp. 219-273 (Boca Raton, FL, CRC Press).
216. SMITH, P. B., COMPTON, D. R., WELCH, S. P., RAZDAN, R. K., MECHOULAM, R. & MARTIN, B. R. (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice, Journal of Pharmacology and Experimental Therapeutics, 270, 219-227.
217. 9-tetrahydrocannabinol and Kappa opioids in mice, Journal of Pharmacology and Experimental Therapeutics, 268, 1381-1387.
218. SNYDER, S. H. (1971) Uses of Marijuana (New York, Oxford University Press).
219. SODERSTROM, C. A., TRIFILUS, A. L., SHANKAR, B. S., CLARK, W. E. & COWLEY, A. (1993) Marijuana and alcohol use among 1023 trauma patients, in: NAHAS, G. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 79-92 (Boca Raton, FL, CRC Press).
220. SOLOWIJ, N. (1996a) The long term effects of cannabis on the central nervous system: I. Brain function and neurotoxicity, World Health Organization Project on Health Implications of Cannabis Use, in press.
221. SOLOWIJ, N. (1996b) The long term effects of cannabis on the central nervous system: II. Cognitive functioning, World Health Organization Project on Health Implications of Cannabis Use, in press.
222. 9-tetrahydrocannabinol, Journal of Leukocyte Biology, 50, 423-426.
223. STILLMAN, R. C., WEINGARTNER, H., WYATT, R. J., GILLIN, C. & EICH, J. (1974) State-dependent (dissociative) effects of marihuana on human memory, Archives of General Psychiatry, 31, 81-85.
224. STRUVE, F. A. & STRAUMANIS, J. J. (1990) Electroencephalographic and evoked potential methods in human marihuana research: historical review and future trends, Drug Development Research, 20, 369-388.
225. STRUVE, F. A., STRAUMANIS, J. J. & PATRICK, G. (1994) Persistent topographic quantitative EEG sequelae of chronic marijuana use: a replication study and initial discriminant function analysis, Clinical Electroencephalography, 25, 63-75.
226. TALBOTT, J. A. & TEAGUE, J. W. (1969) Marihuana Psychosis, Journal of the American Medical Association, 210, 299-302.
227. TAPIA-CONYER, R., CRAVIOTO, P., REVUELTA, A. & DE LA ROSA, B. (1994) Surveillance system of addictions of Mexico (SISVEA), 1991-1993, Epidemiologic Trends in Drug Abuse: Community Epidemiology Work Group, vol. II, pp. 367-379 (Washington, DC, US Department of Health and Human Services).
228. TASCHNER, K. L. (1983) Psychopathology and differential diagnosis of so-called cannabis psychoses, Fortschritte Der Neurologie-psychiatrie, 51, 235-248.
229. TERHUNE, K., IPPOLITO, C., HENDRICKS, D. et al. (1992) The incidence and role of drugs in fatally injured drivers (US Department of Transportation, National Highway Traffic Safety Administration).
230. 9-THC-DMH, Journal of Pharmacology and Experimental Therapeutics, 263, 1383-1390.
231. 9-tetrahydrocannabinol in rhesus monkeys, Toxicology and Applied Pharmacology, 27, 648-665.
232. THORNICROFT, G. (1990) Cannabis and psychosis: is there epidemiological evidence for an association? British Journal of Psychiatry, 157, 25-33.
233. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist, European Journal of Pharmacology, 280, R13-R15.
234. 1 cannabinoid receptor in the hypotensive action of anandamide, European Journal of Pharmacology, 278, 279-283.
235. VOLKOW, N. D. & FOWLER, J. S. (1993) Use of positron emission tomography to study drugs of abuse, in: NAHAS, C. G. & LATOUR, C. (Eds) Cannabis: physiopathology, epidemiology, detection, pp. 21-43 (Boca Raton, CRC Press).
236. 9-tetrahydrocannabinol in men and women, Clinical Pharmacology and Therapeutics, 34, 352-363.
237. WALLACE, J. M., TASHKIN, D. P., OISHI, J. S. & BARBERS, R. G. (1988) Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers, Journal of Psychoactive Drugs, 20, 9-14.
238. WARD, S. J., BAIZMAN, E., BELL, M. et al. (1991) Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? in: HARRIS, L. S. (Ed.) Problems of Drug Dependence 1990: Proceedings of the 52nd Annual Scientific Meeting, pp. 425-426 (Washington, DC, US Govt Printing Office).
239. WARD, S. J., MASTRIANI, D., CASIANO, F. & ARNOLD, R. (1990) Pravadoline: profile in isolated tissue preparations, Journal of Pharmacology and Experimental Therapeutics, 255, 1230-1239.
240. 8-tetrahydrocannabinol in mice, European Journal of Pharmacology, 94, 349-351.
241. WATZL, B., SCUDERI, P. & WATSON, R. R. (1991) Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro, in: FRIEDMAN, H., SPECTOR, S. & KLEIN, T. W. (Eds) Drugs of Abuse, Immunity, and Immunodeficiency, pp. 63-70 (New York, Plenum Press).
242. WECHSLER, H., ROHMAN, M., KOTCH, J. B. & IDELSON, R. K. (1984) Alcohol and other drug use and automobile safety: a survey of Boston-area teen-agers, Journal of School Health, 54, 201-203.
243. WEIDENFELD, J., FELDMAN, S. & MECHOULAM, R. (1994) The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypotholamo-pituitary-adrenal axis in the rat, Neuroendocrinology, 59, 110-112.
244. 9-tetrahydrocannabinol to cannabinoids with therapeutic potential, in: COLPAERT, F. C. & ROSECRANS, J. A. (Eds) Stimulus Properties of Drugs: ten years of progress, pp. 99-122 (Amsterdam, Elsevier/North-Holland Biomedical Press).
245. WELCH, S. P., THOMAS, C. & PATRICK, G. S. (1995) Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine, Journal of Pharmacology and Experimental Therapeutics, 272, 310-321.
246. WERT, R. C. & RAULIN, M. L. (1986) The chronic cerebral effects of cannabis use. II. Psychological findings and conclusions, International Journal of the Addictions, 21, 629-642.
247. 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors, Brain Research, 544, 145-149.
248. WIKLER, A. (1976) Aspects of tolerance to and dependence on cannabis, Annals of the New York Academy of Science, 282, 126-147.
249. 9-tetrahydrocannabinol in rats and rhesus monkeys, Journal of Pharmacology and Experimental Therapeutics, 275, 1-6.
250. WILLIAMS, A., PEAT, M., CROUCH, D., WELLS, J. & FINKLE, B. (1985) Drugs in fatally injured young male drivers, Public Health Reports, 100, 19-25.
251. 9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages, International Journal of Immunopharmacology, 14, 1445-1452.
252. ZUARDI, A. W. & KARNIOL, I. G. (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination, Brazilian Journal of Medical and Biological Research, 16, 141-146.